IMI -Translational approaches to disease modifying therapy of Type 1 Diabetes Mellitus (T1DM)

EU- INNOVATIVE MEDICINES INITIATIVE

Objecte

Specific challenge

Type 1 diabetes mellitus (T1DM) is a chronic disease affecting worldwide around 17 million people. The disease T1DM may present at any age, but most typically presents in early life with a peak around puberty. The incidence rate is highest in Europe, affecting altogether 22 /100.000 per year, with major regional differences and an overall 25% higher incidence rate than in the US (www.diapedia.org). The rising incidence of T1DM appears to be explained by faster conversion from islet-antigen seropositivity to manifest β-cell failure. However, the scientific insights to the triggering events, disease susceptibilities, and subsequent pathophysiological events leading to failing β-cell function and beta cell loss in human disease are quite limited. Rational disease modifying therapeutic approaches to address T1DM are lacking.
 

Termini IISPV

Declaration of interest: IISPV’s deadline: August 31, 2014 (europa@iispv.cat) Full proposal: IISPV’s deadline: October 29, 2014

Termini Oficial

Stage 1 Submission deadline: 12 November 2014 – 17:00:00 Brussels time

Estàs interessat?

Omple el següent formulari per rebre més informació: